搜索
 > 【IL-2】重组蛋白信息

IL-2信息

英文名称:Interleukin-2
中文名称:白细胞介素-2
靶点别称:TCGF,INN=Aldesleukin,Interleukin-2,T-cell growth factor,IL2,IL-2
上市药物数量:2
临床药物数量:23
最高研发阶段:批准上市

IL-2产品列表

货号 物种 产品描述 蛋白结构 纯度 活性
IL2-H4113
Human
Human IL-2 Protein, Tag Free
IL2-H82F3
Human
Biotinylated Human IL-2 Protein, Fc,Avitag

IL-2 分子别名

IL2,TCGF,lymphokine,Interleukin 2

IL-2 分子背景

Interleukin-2 (IL-2) is an interleukin, a type of cytokine immune system signaling molecule, which is a leukocytotrophic hormone that is instrumental in the body's natural response to microbial infection and in discriminating between foreign (non-self) and self. IL-2 mediates its effects by binding to IL-2 receptors, which are expressed by lymphocytes, the cells that are responsible for immunity. Mature human IL-2 shares 56% and 66% aa sequence identity with mouse and rat IL-2, respectively. Human and mouse IL-2 exhibit crossspecies activity. The receptor for IL-2 consists of three subunits that are present on the cell surface in varying preformed complexes. IL-2 is also necessary during T cell development in the thymus for the maturation of a unique subset of T cells that are termed regulatory T cells (T-regs). After exiting from the thymus, T-Regs function to prevent other T cells from recognizing and reacting against "self antigens", which could result in "autoimmunity". T-Regs do so by preventing the responding cells from producing IL-2. Thus, IL-2 is required to discriminate between self and non-self, another one of the unique characteristics of the immune system.

IL-2 参考文献

IL-2上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Recombinant Human Interleukin-2 Injection (Beijing Four Rings Biopharmaceutical) 重组人白介素-2注射液 (北京四环生物制药有限公司) 批准上市 北京四环生物制药有限公司 肾癌, 黑色素瘤
Thalidomide 沙利度胺 NSC-527179,K 17,NSC527179,NSC66847,K-17,NSC-66847,K17,NSC 527179,NSC 66847 批准上市 新基 THALOMID fda 麻风结节性红斑, 多发性骨髓瘤 CELGENE 1998-07-16 麻风结节性红斑, 多发性骨髓瘤 详情

IL-2临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
VPM-4001 VPM-4001; VPM-4-001,VPM 4001; VPM 4 001,VPM4001 临床二期 斯隆-凯特琳癌症中心, Vakzine Projekt Management 前列腺癌
Interleukin-2 (Amgen) 临床二期 安进 癌症
AdCAIL-2 (McMaster University) 临床一期 McMaster University 乳腺癌, 黑色素瘤
Interleukin-2 gene therapy (St Jude Children's Research Hospital) 临床一期 St Jude Children's Research Hospital, 美国国立癌症研究所 成神经细胞瘤
Tucotuzumab celmoleukin EMD-273066; huKS-IL2; KS-IL2 临床二期 EMD Lexigen, 默克雪兰诺 小细胞肺癌, 卵巢癌 详情
Human interleukin-2 biosimilar (BioGeneric Pharma) 临床阶段不明 BioGeneric, 厦门特宝生物工程股份有限公司 不明
Interleukin-2 (Roussel Uclaf) U-49637; RU-49637; IL-2 临床三期 赛诺菲, Transgene 癌症
TG-1031 TG-1031; pTG-1031 临床二期 Transgene 前列腺癌, 乳腺癌
S-95007 S-95007 临床二期 施维雅 免疫炎症, 免疫性疾病
Interleukin-2 controlled release (Avadel Pharmaceuticals) 临床二期 Avadel Pharmaceuticals 肾癌
Cancer vaccine pp65 (Immunomic Therapeutics/Duke University) 临床二期 Immunomic Therapeutics, 杜克大学医学中心 成胶质细胞瘤
HBAI-20 HBAI-20; HBAI-20-CyTuVax 临床二期 CyTuVax 乙肝 详情
IL-2 gene therapy (Imperial Cancer Research Technology) 临床一期 Cancer Research UK 黑色素瘤
TG-4010 TG-4010; VV-MUC-IL2 临床三期 Transgene 非小细胞肺癌 详情
Whole cell vaccine (Oncbiomune) 临床阶段不明 Oncbiomune 乳腺癌
PMI-001 PMI-001,PMI 001,PMI001 临床三期 Phytomedics 红斑样寻常狼疮, 银屑病, 多发性硬化症, 类风湿性关节炎 详情
Interleukin-2 gene therapy (Institute of Cancer Research UK) 临床一期 Institute of Cancer Research 黑色素瘤
Autologous tumor cell vaccine (NCI) 临床二期 H. Lee Moffitt Cancer Center and Research Institute, 美国国立癌症研究所, Chiron 肾癌 详情
AC-9401 AC-9401 临床二期 AntiCancer Inc 癌症
ALVAC-hIL-2 ALVAC-IL-2; ALVAC-hIL-2,ALVAC-IL 2; ALVAC-hIL 2,ALVAC-IL2; ALVAC-hIL2,vCP277 临床二期 Sanofi Pasteur 癌症
Mab-33B3.1 (Immunotech) MAb-33B3.1,MAb33B3.1; 33B3.1 临床二期 赛诺菲, Immunotech 移植物抗宿主病
Interleukin-2 gene therapy (Valentis) 临床二期 Valentis 肺癌, 头颈癌, 黑色素瘤
DAB-486-IL-2 临床二期 Seragen, 礼来 1型糖尿病, 艾滋病, 淋巴瘤, 类风湿性关节炎, Kaposis肉瘤

消息提示

请输入您的联系方式,再点击提交!

确定